Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Thursday, July 2
OR L ESINS110 -12.01.0- 12.3

B41 Care in Special Populations
Chairs: Shaun Mellors, Robert Shearer
Venue: Session Hall III
Time: 11.00-12.30
499 Virologic response to antiretroviral therapy among 32407
HIV-infected injection drug users
Wafaa EI-Sadr*; Sharon Mannheimer;J. Flowers;
H. Safavi;J. Curtis, USA
500 Barriers to HIV antiretroviral therapy among injection 42285
drug users in settings with and without
universal health insurance coverage
David Celentano*; R.S. Hogg; D. Vlahov; S.A. Strathdee;
R.D. Moore; A. Palepu; S. Cohn, USA
501 Prisons and public health: Emerging issues in HIV 32408
treatment adherence
Linda Frank, USA
502 Continuity of medical care and risk of incarceration in 32411
HIV+ and HIV- high risk women
Mary Sheu*; Timothy Flanigan; TR Flanigan;J. Allsworth;
J. Hogan; M.D. Stein; D. Vlahov; E. Schoenbaum, USA
503 Health status and co-morbidity of HIV+ and 32409
HIV- out-of-treatment injection drug users (IDUs)
Frederick Altice*; K. Khooshnood; K.M. Blankenship;
C.T. Roan; M. Kravitz, USA
504 Pozfit, positively fit: A prospective, pilot project in 42400
community-based HIV rehabilitation services
Gerry Bally*; G.R. Murphy, Canada
505 Palliative care for HIV-infection in a skilled nursing facility 22427
Peter A. Selwyn*; K.R Fennie; S. Molde; J. Constantino, Sr.;
P. Wetherill; L. Goldman; C. Kennedy, USA
B42 Predictors of Response to Antiretroviral Treatment o
Chairs: Jonathan Anderson, Peter Mugyenyi
Venue: Session Hall IV
Time: 11.00-12.30
506 HIV RNA, CD4+ cell count, and immune activation markers 32167

B43 HIV-infection in Children
Chairs: Luke Chipperfield, Connie Mwaise Osborne
Venue: Arena
Time: 11.00-12.30
513 Markers for diagnosis and for monitoring therapy in children
John Ziegler
514 Clinical management in the North
Sandra Burchett
515 Clinical management in resource-poor settings
SunitiSolomon
516 Palliative care for children
Jim Oleske
C41 Trends and Patterns of HIV Epidemics
Chairs: Jordi Casabona, Euclides Castilho
Venue: Session HallV
Time: 11.00-12.30

517 HIV-infection in young men in Northern Thailand, 1991-1997,
increasing role of injection drug use
Kenrad Nelson*; S. Eiutrakul; D.D. Celentano; C. Beyrer;
S. Kuntolbutra; C. Khamboonruang, USA
518 Epidemiology of HIV-1 seroconversion among young adults
in the U. S.Army, 1985-1996: Current trends in an evolving
epidemic
Philip Renzullo*; H. Bacellar; R.P. Garner; D.L. Birx;
J. G. McNeil, USA
519 Risk for HIV-1 seroconversion in the Ugandan people's
defense forces
Kathleen George*; D. Hom;J.McGrath; J.L.Johnson;
P Mugyenyi; R. Mugerwa;J. Ellner, Uganda
520 Annual HIV incidence decreased among persons with
sexually transmitted diseases (STD) in Italy between
1988 and 1994
Barbara Suligoi*; M. Giuliani; M. Balducci; N. Galai, Italy
521 HIV in the Philippines: Analysis of data from the National
HIV Sentinel Surveillance System
Maria Consoria Lim-Quizon*; M.CR. Roces; W. Cuenco;
A.E. Ghee; G. Poumerol; S. Omi, Philippines
522 The HIV/AIDS epidemic in Europe: Changing trends
and new challenges
Francoise F. Hamers*;A.M. Downs;A. Infuso;J.B. Brunet,
France

43555

13212
23507
13281
43508
13179

predict HIV-related wasting prior to AIDS in the
Multicenter AIDS Cohort Study (MACS)
Robert H. Lyles*; A.M. Tang; J. W. Mellors; J.B. Margolick;
B.R. Visscher; J.P. Phair; N.M.H. Graham, USA
507 HIV serum RNA, CD4 cell numbers and risk for clinical
endpoints in a case-cohort study of ACTG 175
David Katzenstein*; S. Kim; M. Hughes; S. Hammer;
V Degruttola, USA
508 Phosphorylation rate of 3"-azidothymidine in maternal
and fetal peripheral blood mononuclear cells at term
RiadAgbaria*; J. Barak; E. Manor;,J. Balzarini, Israel
509 Zidovudine (ZDV) phosphorylation determined at intervals
over 12 months in naive and antiretroviral experienced
HIV+ patients
PG. Hoggard*; David J. Back; S.E. Gibbons; J. Lloyd; M.G. Barry;
S.H. Khoo; C. Loveday, UK
510 The rate of decline of HIV-1 RNA in plasma correlates with
nelfinavir concentrations in plasma
Richard M. W. Hoetelmans*; M.H.E. Reijers; G.F. Weberling;
S. Furriaans; F.M.A. Lange, The Netherlands
511 Plasma concentrations of saquinavir (SQV) determine
HIV-1 RNA response over a 48-week period
RichardM. W. Hoetelmans*; R.P.G. Heeswijk, Van;
P.L. Meenhorst; F. W. Mulder; W.A. Scheele; F.H. Beijnen,
The Netherlands
512 Saliva as a possible specimen for monitoring compliance
and plasma levels in patients treated with indinavir (IDV)
Patricia W.H. Hugen*; D.M. Burger; R.M. W. Hoetelmans;
K. Brinkman; P.L. Meenhorst; J. W. Mulder; P.P. Koopmans,
The Netherlands
Pathw
178

12124

42258
42260
42259
42261
32330
Nay Symbol: 0 Youth and Children

12th World AIDS Conference Geneva